What is Fenbendazole?
Fenbendazole is a benzimidazole anthelmintic with a veterinary background. Its experimental anticancer literature is separate from demonstrated human cancer treatment.
Mechanism & research focus
Laboratory work has examined disruption of microtubule dynamics, changes in glucose handling and other cell-stress pathways. Cytotoxicity in cultured cancer cells is a mechanistic observation, not evidence of selective benefit in patients.
What the research covers
A 2018 study reported cell-growth effects and inhibition of tumor xenografts in mice. Human case reports instead raise safety concerns: a 2026 report assessed severe liver injury associated with self-administered fenbendazole in an oncology patient.
What remains uncertain
The cited experiments do not establish human anticancer efficacy. A case report cannot estimate the frequency of liver injury, but it contradicts blanket safety claims. Animal antiparasitic use and preclinical tumor findings cannot validate a commercial product for human treatment.
The evidence label describes the linked research, not the suitability of a catalog product for use in people. Formulation, identity, purity, and measured content must be assessed separately.
Sources & studies
Fenbendazole affects microtubules and multiple pathways in cancer models ↗
Mechanistic cancer-cell and xenograft experiments; not a human efficacy trial.
Differentiating fenbendazole-induced liver injury from immunotherapy hepatitis ↗
Structured assessment of suspected drug-induced liver injury; no cancer-efficacy inference.
Read the full paper for its design, controls and limitations. A source link is not a claim that its tested material matches a DA formulation.
Catalog formats & documentation
Formats grouped by compound identity. Availability and batch documentation remain on Disguised Alpha.
Original DA reference: Fenbendazole research guide ↗